Celcuity LLC (CELC) - Total Assets
Based on the latest financial reports, Celcuity LLC (CELC) holds total assets worth $476.00 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Celcuity LLC stock quote for real-time trading data and today's change.
Celcuity LLC - Total Assets Trend (2015–2024)
This chart illustrates how Celcuity LLC's total assets have evolved over time, based on quarterly financial data. Also see Celcuity LLC (CELC) cash flow conversion for how efficiently the company converts equity into cash flow.
Celcuity LLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Celcuity LLC's total assets of $476.00 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.2% |
| Accounts Receivable | $1.60 Million | 0.7% |
| Inventory | $-8.63 Million | -3.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Celcuity LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Celcuity LLC's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celcuity LLC's current assets represent 99.8% of total assets in 2024, an increase from 96.7% in 2015.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2024, down from 95.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Celcuity LLC Competitors by Total Assets
Key competitors of Celcuity LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $35.32 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $1.15 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Celcuity LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.26 | 10.36 | 10.26 |
| Quick Ratio | 12.26 | 10.36 | 10.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $436.70 Million | $246.13 Million | $10.98 Million |
Celcuity LLC - Advanced Valuation Insights
This section examines the relationship between Celcuity LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.34 |
| Latest Market Cap to Assets Ratio | 17.95 |
| Asset Growth Rate (YoY) | 28.2% |
| Total Assets | $245.12 Million |
| Market Capitalization | $4.40 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Celcuity LLC's assets at a significant premium (17.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Celcuity LLC's assets grew by 28.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Celcuity LLC (2015–2024)
The table below shows the annual total assets of Celcuity LLC from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $245.12 Million | +28.19% |
| 2023-12-31 | $191.22 Million | +8.83% |
| 2022-12-31 | $175.70 Million | +104.52% |
| 2021-12-31 | $85.91 Million | +563.02% |
| 2020-12-31 | $12.96 Million | -36.11% |
| 2019-12-31 | $20.28 Million | -22.09% |
| 2018-12-31 | $26.03 Million | -18.57% |
| 2017-12-31 | $31.97 Million | +427.81% |
| 2016-12-31 | $6.06 Million | +14.28% |
| 2015-12-31 | $5.30 Million | -- |
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more